行业估值方面，地产行业市盈率（TTM）平均值为4.79倍，行业中值-0.15倍。宏辉集团市盈率-0.63 倍，行业排名第194位；其他百仕达控股（01168.HK）为0.3倍、百仕达控股（02983.HK）为0.35倍、恒 达集团控股（03616.HK）为1.71倍、美联集团（01200.HK）为2.37倍、瑞森生活服务（01922.HK）为 2.82倍。 资料显示，宏辉集团控股有限公司(宏辉集团)自二零一零年起在香港联交所主板上市。宏辉集团有三大 核心业务──物业开发及投资、室内设计及建筑工程、组合投资及管理。物业开发及投资是公司的核心 业务之一,旗下组合可带来长远稳定收入。经多年的增长,公司的业务范畴已扩大至提供室内设计及建筑 服务和组合投资及管理业务,本集团的资产值超过港币22亿元。公司扎根香港,一直于中国、英国、日 本、德国、柬埔寨及美利坚合众国('美国')等地扩展业务及加大投资。集团上下致力在香港扩大业务规 模,同时增加于海外的长远商业利益,藉此为股东及投资者缔造最丰硕的回报。 大事提醒 5月28日，截至港股收盘，恒生指数下跌0.53%，报23258.31点。宏辉集团（00183.HK）收报0.25 ...

Company Overview - Hengchang Group International primarily engages in electrical engineering services, solar business (supply and installation of solar photovoltaic components and equipment), and distribution system business (supply of distribution systems including distribution boards, junction boxes, cables, and switches) in China [3] - The company is recognized as one of the established electrical engineering firms in Singapore for public housing projects and is a participant in China's solar and distribution system sectors [3] - The competitive advantage lies in the experienced management team providing reliable and cost-competitive solutions [3] Financial Performance - As of December 31, 2024, Hengchang Group International reported total revenue of 50.61 million yuan, a year-on-year decrease of 13.41% [2] - The net profit attributable to the parent company was -15.10 million yuan, showing a year-on-year increase of 41.02% [2] - The gross profit margin stood at 6.39%, with a debt-to-asset ratio of 32.84% [2] Stock Performance - As of May 28, the stock price closed at 0.205 HKD per share, reflecting a 19.19% increase with a trading volume of 11.39 million shares and a turnover of 2.27 million HKD, showing a volatility of 27.91% [1] - Over the past month, the stock has experienced a cumulative decline of 14%, and a year-to-date decline of 21.82%, underperforming the Hang Seng Index which has increased by 16.56% [2] Valuation Metrics - Currently, there are no institutional investment ratings for Hengchang Group International [2] - The average price-to-earnings (P/E) ratio for the construction industry (TTM) is 10.55 times, with a median of 1.58 times; Hengchang Group International's P/E ratio is -0.8 times, ranking 205th in the industry [3]

5月28日，北部湾港今日收盘8.56元，下跌2.62%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到19.45倍，总市值199.12亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)24北部湾港19.4516.331.13199.12亿行业平均 13.6315.271.18290.35亿行业中值14.4214.871.16130.84亿1国航远洋-644.51248.014.1856.21亿2凤凰航 运-61.15-57.3910.4047.47亿3*ST锦港-0.27-0.27-12.5217.42亿4中远海控4.715.181.042543.61亿5招商南油 8.486.771.17130.13亿6上港集团8.848.970.981341.01亿7青岛港10.6010.781.28564.08亿8招商轮船 10.759.681.22494.16亿9中远海特11.0111.041.03169.03亿10招商港口11.2411.370.82513.53亿11秦港股份 11.7411.640.92182.15亿 本文源自：金融界 作者：行情君 截至2025年一季报，共有19家机构持仓 ...

Group 1 - The core viewpoint of the article highlights that Furuya Co., Ltd. has seen a stock price increase of 5.15% to 33.47 yuan, with a rolling PE ratio of 89.87, marking a new low in 44 days, and a total market capitalization of 8.915 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical device industry is 49.11, with a median of 35.89, placing Furuya Co., Ltd. at the 106th position in the industry ranking [1] - The company reported a net inflow of 16.2962 million yuan in main funds on May 27, with a total inflow of 38.9964 million yuan over the past five days, indicating a positive trend in fund flow [1] Group 2 - Furuya Co., Ltd. specializes in the production and sales of drugs in the field of liver disease, development and sales of diagnostic equipment, and related medical services, with its main product being the Compound Turtle Shell Soft Liver Tablets [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 330 million yuan, a year-on-year increase of 2.35%, while net profit was 28.6367 million yuan, reflecting a year-on-year decrease of 32.97%, with a gross profit margin of 76.76% [1]

文 | 银行螺丝钉 （转载请注明出处） 今天大盘开盘上涨，之后盘中下跌，到收盘跌幅收窄，还在5星。 沪深300大盘股下跌。 中证1000、2000等小微盘股指数上涨。 红利等价值风格微跌。 创业板等成长风格下跌较多。 港股也下跌。港股红利比较坚挺，略微波动。 港股科技股下跌较多。 春节后一波上涨，港股科技指数回到正常估值。 4月初港股科技下跌，回到低估；之后连续5周上涨，回到正常估值。 最近财报更新，港股科技盈利增长，带动估值降低。 今天下跌之后，港股科技指数也回到低估了。 以港股科技指数为例。 2024年10月国庆节后大涨，首次回到正常估值，当时在2800点上下。 中证1000属于小盘股指数。 过去几年，因为经济低迷，上市公司的盈利出现波动。 其中，中证1000指数， 2023年，盈利下降17.8%； 2024年，盈利下降2.44%。 不过今年一季度，小盘股盈利有企稳回升的迹象，中证1000在2025年1季度的盈利同比增长16%。 春节后一波大涨再次回到正常估值，在2900点上下。 最近财报更新，在3000多点，在正常和低估边界上。 同样的估值，因为上市公司盈利增长，推动指数的点数还是逐渐上涨的。 1. 有 ...

雪龙集团（603949）发布异动公告，外部流通股占比为29.20%，相对较小，可能存在非理性炒作风 险。目前公司静态市盈率78.74，滚动市盈率80.26，均显著偏离同行业平均水平。经公司自查，公司目 前生产经营正常。市场环境、行业政策没有发生重大调整，生产成本和销售等情况没有出现大幅波动， 内部生产经营秩序正常。 ...

Company Overview - Dirui Medical's closing price on May 26 was 13.33 yuan, down 1.48%, with a rolling PE ratio of 101.54 times and a total market value of 3.635 billion yuan [1] - The company ranks 107th in the medical device industry, which has an average PE ratio of 48.92 times and a median of 35.68 times [1][2] - Dirui Medical specializes in the research, production, marketing, and service of medical testing instruments and related reagents, with key products including urine analysis, biochemical analysis, chemiluminescence immunoassay, gynecological secretion analysis, blood cell analysis, coagulation analysis, and overall laboratory solutions [1] Financial Performance - In the first quarter of 2025, Dirui Medical reported operating revenue of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.6787 million yuan, down 87.13% year-on-year, with a gross profit margin of 42.78% [1] - Over the past five days, the company experienced a net outflow of main funds amounting to 677,700 yuan, totaling 5.8154 million yuan in outflows [1]

5月26日，尚荣医疗今日收盘3.62元，下跌2.43%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到136.87倍，总市值30.61亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入2.80亿元，同比1.30%；净利润1396.42万元，同 比0.58%，销售毛利率15.27%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)111尚荣医疗136.87137.361.1630.61亿行业平均 48.9247.334.59105.60亿行业中值35.6837.002.4048.12亿1天益医疗-1741.60-2983.161.8622.19亿2澳华内 镜-632.39317.185.0766.65亿3诺唯赞-396.61-469.092.1884.88亿4爱朋医疗-353.16268.304.2528.98亿5博晖 创新-319.03506.263.4046.81亿6硕世生物-133.10-1944.971.1938.93亿7奥精医疗-129.86-190.331.7124.10亿 8睿昂基因-100.04-82.131.4212.95亿9康泰医学-85.53-72.263. ...

智通财经5月26日电，苏州龙杰(603332.SH)公告称，公司股票连续2个交易日内收盘价格涨幅偏离值累 计达20%，属于股票交易异常波动情况。公司基本面未发生重大变化，也不存在应披露而未披露的重大 信息。截至5月26日，根据东方财富网发布的相关数据显示，公司股票换手率5.19%；公司TTM市盈率 66.98，行业中值TTM市盈率31.64，公司TTM市盈率略高于行业中值水平。公司股价短期波动幅度较 大，郑重提醒广大投资者充分了解二级市场交易风险，理性投资、注意投资风险。 12天8板苏州龙杰：公司TTM市盈率略高于行业中值水平 ...

5月26日，泰山石油今日收盘6.27元，上涨1.13%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到22.54倍，总市值30.15亿元。 从行业市盈率排名来看，公司所处的石油行业行业市盈率平均12.63倍，行业中值25.57倍，泰山石油排 名第14位。 股东方面，截至2025年5月20日，泰山石油股东户数34768户，较上次减少416户，户均持股市值35.28万 元，户均持股数量2.76万股。 最新一期业绩显示，2025年一季报，公司实现营业收入8.02亿元，同比-4.76%；净利润5296.57万元，同 比185.74%，销售毛利率17.68%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)14泰山石油22.5430.352.7630.15亿行业平均 12.6311.321.171698.99亿行业中值25.5729.381.5653.24亿1茂化实华-26.67-23.823.2419.86亿2沈阳化 工-25.70-18.142.1630.49亿3中晟高科-20.05-13.477.4922.93亿4博汇股份-9.52-7.917.2124.28亿5国际实 业-5.92-5.9 ...